Switch theme
Sign up to access all valuation multiples
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
1999
38
LTM Revenue $13.4M
LTM EBITDA $5.1M
$166M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genovis has a last 12-month revenue (LTM) of $13.4M and a last 12-month EBITDA of $5.1M.
In the most recent fiscal year, Genovis achieved revenue of $13.4M and an EBITDA of $6.3M.
Genovis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genovis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.4M | XXX | $13.4M | XXX | XXX | XXX |
| Gross Profit | $11.9M | XXX | $11.9M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $5.1M | XXX | $6.3M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 47% | XXX | XXX | XXX |
| EBIT | $4.1M | XXX | $3.0M | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $2.7M | XXX | $3.4M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genovis's stock price is SEK 26 (or $3).
Genovis has current market cap of SEK 1.7B (or $176M), and EV of SEK 1.6B (or $166M).
See Genovis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $166M | $176M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genovis has market cap of $176M and EV of $166M.
Genovis's trades at 12.4x EV/Revenue multiple, and 26.6x EV/EBITDA.
Equity research analysts estimate Genovis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genovis has a P/E ratio of 65.3x.
See valuation multiples for Genovis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $176M | XXX | $176M | XXX | XXX | XXX |
| EV (current) | $166M | XXX | $166M | XXX | XXX | XXX |
| EV/Revenue | 12.4x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBITDA | 32.4x | XXX | 26.6x | XXX | XXX | XXX |
| EV/EBIT | 40.9x | XXX | 54.8x | XXX | XXX | XXX |
| EV/Gross Profit | 14.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 65.3x | XXX | 51.8x | XXX | XXX | XXX |
| EV/FCF | 64.7x | XXX | 49.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenovis's last 12 month revenue growth is 8%
Genovis's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Genovis's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genovis's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genovis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | -22% | XXX | XXX | XXX |
| Rule of 40 | 50% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genovis acquired XXX companies to date.
Last acquisition by Genovis was XXXXXXXX, XXXXX XXXXX XXXXXX . Genovis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genovis founded? | Genovis was founded in 1999. |
| Where is Genovis headquartered? | Genovis is headquartered in Sweden. |
| How many employees does Genovis have? | As of today, Genovis has 38 employees. |
| Who is the CEO of Genovis? | Genovis's CEO is Mr. Fredrik Olsson. |
| Is Genovis publicy listed? | Yes, Genovis is a public company listed on STO. |
| What is the stock symbol of Genovis? | Genovis trades under GENO ticker. |
| When did Genovis go public? | Genovis went public in 2005. |
| Who are competitors of Genovis? | Similar companies to Genovis include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Genovis? | Genovis's current market cap is $176M |
| What is the current revenue of Genovis? | Genovis's last 12 months revenue is $13.4M. |
| What is the current revenue growth of Genovis? | Genovis revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Genovis? | Current revenue multiple of Genovis is 12.4x. |
| Is Genovis profitable? | Yes, Genovis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genovis? | Genovis's last 12 months EBITDA is $5.1M. |
| What is Genovis's EBITDA margin? | Genovis's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Genovis? | Current EBITDA multiple of Genovis is 32.4x. |
| What is the current FCF of Genovis? | Genovis's last 12 months FCF is $2.6M. |
| What is Genovis's FCF margin? | Genovis's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Genovis? | Current FCF multiple of Genovis is 64.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
